Inspire Medical Systems (NYSE:INSP) 2026 Conference Transcript

Summary of Inspire Medical Systems Conference Call Company Overview - Company: Inspire Medical Systems (NYSE: INSP) - Industry: Medical Technology, specifically focused on obstructive sleep apnea (OSA) treatment Key Points and Arguments Leadership and Strategic Focus - The new CFO, Matt Osberg, expressed excitement about joining Inspire and highlighted the company's growth potential and market opportunities in OSA treatment [3][4] - The company aims to continue investing in R&D to enhance product capabilities while driving profitable growth [4][5] Financial Performance - Inspire reported a strong end to 4Q25 with mid-teens revenue growth and substantial earnings growth [6] - For 1Q26, the company anticipates flat growth due to reimbursement challenges, particularly related to coding issues and the WISeR program [6][8] Reimbursement Dynamics - Reimbursement issues are impacting procedures, with confusion among centers and physicians leading to delays [8][9] - A new CPT code application for the Inspire V procedure is under review, with a potential approval timeline aiming for January 1, 2028 [10][11] - CMS has issued C codes for the Inspire V procedure, effective April 1, 2026, which will maintain current payment levels of approximately $32,000 for hospitals and $27,000 for ASCs [12][13] WISeR Program - The WISeR program, requiring prior authorization for Medicare cases in six states, has faced initial challenges but is expected to improve as the company gains experience [14][15] Product Launch and Market Acceptance - The full market launch of Inspire V has been successful, with over 90% of centers engaged and strong acceptance from healthcare providers [39] - The Inspire V system has shown improved patient outcomes, with a 79.5% responder rate in the Singapore study, compared to 64% in previous trials [42] Clinical Data and Patient Engagement - Patients using the Inspire V therapy are averaging 6.3 hours of use per night, significantly improving their apnea-hypopnea index (AHI) from an average of 30 to below 10 events per hour [46][47] - The removal of the pressure-sensing lead in the Inspire V has reduced operating room time and improved reliability [43] Competitive Landscape - Inspire acknowledges the presence of new competitors, such as Nyxoah, but remains confident in the established efficacy and support of Inspire V [60] Profitability and Growth Strategy - Inspire aims to balance revenue growth with profitability, continuing to invest in product development while improving operating margins [61][62] - The company emphasizes its strong technology and commitment to addressing reimbursement challenges to enhance patient outcomes [63][64] Additional Important Insights - Inspire is transitioning to a new manufacturing line for Inspire V, indicating strong inventory support for future activities [44] - The company is exploring future enhancements, including software upgrades and potential new stimulation targets for high BMI patients [58][59] This summary encapsulates the key discussions and insights from the Inspire Medical Systems conference call, highlighting the company's strategic direction, financial outlook, product performance, and market dynamics.